Nanofiltration of plasma-derived biopharmaceutical products.
about
Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical useInactivation of Zika virus by solvent/detergent treatment of human plasma and other plasma-derived products and pasteurization of human serum albuminAnti-Human Platelet Antigen-1a Immunoglobulin G Preparation Intended to Prevent Fetal and Neonatal Alloimmune ThrombocytopeniaHAE therapies: past present and future.Chemical and biological mechanisms of pathogen reduction technologiesMinipool caprylic acid fractionation of plasma using disposable equipment: a practical method to enhance immunoglobulin supply in developing countries.Treating haemophilia A with recombinant blood factors: a comparison.Pathogen inactivation technology: cleansing the blood supply.Haemophilia B: Christmas disease.The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics.Microfluidic devices with templated regular macroporous structures for HIV viral captureHaemophilia therapies.Pharmacotherapy of haemophilia A.The new era of C1-esterase inhibitor deficiency therapy.Nanofiltered human C1 inhibitor concentrate (Cinryze®): in hereditary angioedema.Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.Innovative approach for improved rFVIII concentrate.The role of Rixubis™ in the treatment of hemophilia B.The present state of the art in expression, production and characterization of monoclonal antibodies.Continuous Manufacturing of Recombinant Therapeutic Proteins: Upstream and Downstream Technologies.A novel virally inactivated human platelet lysate preparation rich in TGF-beta, EGF and IGF, and depleted of PDGF and VEGF.Inactivation of parvovirus B19 during STIM-4 vapor heat treatment of three coagulation factor concentrates.Micropatterned macroporous structures in microfluidic devices for viral separation from whole blood.Removal of small non-enveloped viruses by nanofiltration.Enveloped virus inactivation using neutral arginine solutions and applications in therapeutic protein purification processes.Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance.Managing haemophilia for life: 4th Haemophilia Global Summit.Implementation of a hepatitis A prevention policy in haemophiliacs: results from the French cohort.Interactions between protein molecules and the virus removal membrane surface: Effects of immunoglobulin G adsorption and conformational changes on filter performance.Resistance of porcine circovirus and chicken anemia virus to virus inactivation procedures used for blood products.Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III sRecombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial.Guidelines for the management of hemophilia.Parvovirus B19 transmission by a high-purity factor VIII concentrate.Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation.Nanofiltration to remove microparticles and decrease the thrombogenicity of plasma: in vitro feasibility assessment.Human platelet concentrates: a source of solvent/detergent-treated highly enriched brain-derived neurotrophic factor.New promise and hope for treating hereditary angioedema
P2860
Q26741073-190BF712-7C39-401C-8E6B-DAB8BAB6FE6EQ28114690-2450C643-A433-4C92-9F6B-CE6A7563DF0DQ33435351-5689A837-9208-4D30-8B02-E927143F24E2Q34063768-59EDA2BD-F907-4112-84D2-CBBB726D15CEQ34777948-7FB25611-AFC2-446C-8872-4A91CE7C63A0Q35125865-B90A58D8-8D44-4AA2-8682-AFA9FAF6C27BQ35779195-8F20D017-7F8C-4FA7-AFB1-E5CC3D63CD92Q36044573-E2F62CD2-AAE9-44EC-88EF-D5CC1F12598AQ36221979-8BC80373-BEDB-4B9E-ADB8-93C1FE95A1FCQ36236913-5C9B449A-F6DB-404F-8B33-E8D3ED76DA9CQ36614097-F864D74A-8AE8-48FC-A681-BA242E9C00A5Q36810282-97EE28E2-0398-4DBA-82A5-B28BA6A45F13Q37891089-976E46A3-37DB-4ACE-BC61-9C62BAB57154Q37915379-3133EA2D-D6CD-47B5-97E3-AA8B3E0E6FE3Q37937702-E0AC2E70-8E62-4172-A2A2-AEEC1B648F09Q38151843-26ACBDBD-A2D6-4544-B439-1AA2BD493969Q38207134-9815BCA7-B684-4541-8C12-0BE7E938C96CQ38210808-F872C83A-D434-4029-8514-D849E061E43BQ38572163-4B1D2D27-3F81-46EB-B550-64988367B180Q39164854-6A4FB221-AE5D-41B3-9B1B-46A9F07D07A3Q39683420-72232191-1B6F-45E3-81A5-9B24848261A5Q39992302-39911F4E-08DE-4150-922E-174EEE20F187Q40181619-07AAE912-C6E1-4756-9F8F-844997BBB8F6Q40555869-3AA55777-B033-4F46-82CE-C26CA7C1988AQ42244307-FF8EE4E4-27D1-470B-A8F3-BE7EEBF97EF1Q42285404-3320620D-CE98-4A54-A3D6-950E2033F175Q42997771-8683379A-55E0-45DC-85B6-6B12068D6089Q44122887-2A719A76-A600-4D35-BDC4-E5C6BA416B23Q45084513-3A18BD0B-0F92-4D57-95F4-AF42EC75620EQ45323943-8AF6E5B6-8963-4A73-825D-ADDFA33E3FD6Q45410532-35749C86-1E05-4B70-9C4C-486E341B36E9Q45863817-4A460059-F3C7-495F-ADAE-40C1E0F39BB0Q45871094-4D558B92-F144-48F5-9EEE-C92EA89618D3Q45880345-1776FEA3-47F6-475D-902B-F06E6A5D1C90Q47786736-2CEDFD90-BC7D-48DA-8BAD-FDFB7D188A96Q48595468-72D8A826-9EEB-4569-8514-DF90B887E3A6Q48669003-93C5CF9A-F164-4C76-943D-473866B350F9Q48733918-CBFDC957-7D93-4D07-8FC7-14CD390EBE55Q58615572-8FFD81D1-D269-4E17-8C4E-4C6BB08FF494
P2860
Nanofiltration of plasma-derived biopharmaceutical products.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Nanofiltration of plasma-derived biopharmaceutical products.
@ast
Nanofiltration of plasma-derived biopharmaceutical products.
@en
type
label
Nanofiltration of plasma-derived biopharmaceutical products.
@ast
Nanofiltration of plasma-derived biopharmaceutical products.
@en
prefLabel
Nanofiltration of plasma-derived biopharmaceutical products.
@ast
Nanofiltration of plasma-derived biopharmaceutical products.
@en
P2860
P1433
P1476
Nanofiltration of plasma-derived biopharmaceutical products.
@en
P2093
Radosevich M
P2860
P356
10.1046/J.1365-2516.2003.00701.X
P577
2003-01-01T00:00:00Z